Efficacy of tranexamic acid in preventing postpartum haemorrhage in vaginal delivery

G. Anantha Lakshmi Satyavathi, Chandrika K.*

Department of Obstetrics and Gynecology, GSL Medical College and General Hospital, Rajahmundry, Andhra Pradesh, India

Received: 30 July 2019
Accepted: 07 August 2019

*Correspondence:
Dr. Chandrika K.,
E-mail: chandrikakanne@yahoo.co.in

ABSTRACT

Background: Postpartum blood loss is difficult to evaluate especially in developing countries like India where most of the women are anaemic with poor reserve and these conditions are further aggravated by increased demand during pregnancy and blood loss during third stage of labour. The present study was planned to compare the efficacy of prophylactic 10 IU intramuscular oxytocin and 10 IU intramuscular oxytocin +1g Tranexamic acid in reducing blood loss in the third stage of labour.

Methods: The present study was carried out on full term pregnancies primigravida/ multiparas with singleton pregnancy being delivered vaginally at GSL Hospital, Rajahmundry between 2016-2017 were included. For this comparative study, 200 women in labor were included after obtaining informed consent. A detailed obstetric history, history of previous medical illnesses, history of the treatment received earlier, cardiovascular and respiratory system and other systems including thyroid and breast were noted.

Results: The average total blood loss in IIIrd stage of labour with IM oxytocin was 210 ml and with IM oxytocin + Tranexamic acid was130 ml, which was statistically significant (p<0.001). Oxytocin + Tranexamic acid group had less blood loss when compared to oxytocin group alone. Side effects like, nausea vomiting, headache were slightly more with oxytocin + Tranexamic acid group when compared to oxytocin group alone.

Conclusions: In the active management of IIIrd stage of labour 10 IU intramuscular Oxytocin + one gram of tranexamic acid IV is a better combination in reducing the blood loss at delivery when compared to 10 IU intramuscular oxytocin alone.

Keywords: Blood loose, Oxytocin, Postpartum haemorrhage, Third stage labour, Tranexamic acid, Vaginal delivery

INTRODUCTION

Postpartum haemorrhage (PPH) is a major cause of maternal mortality, accounting for one quarter of all maternal deaths worldwide with an incidence from 3% to 15% of deliveries.

Postpartum blood loss is difficult to evaluate especially in developing countries like India where most of the women are anaemic with poor reserve and these conditions are further aggravated by increased demand during pregnancy and blood loss during third stage of labour.1

Two thirds of postpartum haemorrhage occurs in women with no identifiable risk factors. Without proper management, PPH can rapidly progress to cause life threatening blood loss, often within few hours. Because
of this unpredictability and rapid progression, for reducing the incidence of PPH and improving PPH outcome it does often remains a challenge, where maternal mortality is high and resources are limited.\(^2\) The introduction of low cost evidence based practices to prevent and manage PPH can improve maternal and infant survival. Routine practice of active management of third stage of labour (AMTSL) has been dramatically reduced haemorrhage by up to 60%.

Active management of the third stage of labor is for the prevention of postpartum haemorrhage as per WHO guidelines. Postpartum haemorrhage (PPH) is classically defined as blood loss of 500mL or more after vaginal delivery. With an incidence from 3% to 15% of deliveries, about one in five of these haemorrhages progresses to a severe form that may endanger the mother’s life or at least her future fertility and exposes her to the risks of transfusion, surgery, and intensive care. PPH remains a leading cause of maternal mortality and accounts for about one quarter of all maternal deaths worldwide. Its risk factors include previous PPH, primiparity, obesity, prolonged or Augmented labor, multiple pregnancy, previous cesarean delivery, polyhydramnios, and macrosomia.\(^3,4\)

Active management of the third stage of labour (AMTSL) first described in the UK and in Ireland, consisted, as initially conceived, of a combination of the following interventions, preventive administration of uterotonic agents immediately after delivery of the child, early cord clamping and cutting, controlled cord traction (CCT) 5 and, according to some authors, uterine massage.

Administration of uterotonics\(^6\) and in particular oxytocin, after birth is the only component of AMTSL that is effective in preventing PPH. However, in addition to this enhancement of mechanical haemostasis, a complementary biochemical haemostatic effect might be expected from the complementary use of prohaemostatic drugs such as tranexamic acid.

Based on this framework the present study is aimed at comparing the efficacy of prophylactic 10 IU intramuscular oxytocin and 10 IU intramuscular oxytocin +1g Tranexamic acid in reducing blood loss in the third stage of labour.

Objective of this study were to determine efficacy and safety of tranexamic acid in preventing postpartum haemorrhage in vaginal delivery.

**METHODS**

The present study was carried out on full term pregnancies primigravida/ multipara (parity not more than two) with singleton pregnancy being delivered vaginally were included in the study at GSL Hospital, Rajahmundry between 2016-2017. For this comparative study, 200 women in labor were included after obtaining informed consent.

All of them had routine antenatal investigations including hemoglobin estimation, packed cell volume, blood grouping and typing, screening for blood sugar, VDRL, HbsAg, HIV with consent, urine routine, ultrasonography, repeat Hb% and PCV on day two after delivery.

100 women were allotted to group-I (IM oxytocin) and 100 women to Group-II (IM oxytocin +Tranexamic acid).

The data was collected in a specified proforma.

**Inclusion criteria**

- Primi gravida and multigravida with singleton pregnancy
- Planned vaginal delivery
- Term ≥ 37weeks of gestation.

**Exclusion criteria**

- Presence History of venous (deep vein thrombosis and/or pulmonary embolism) or arterial (angina pectoris myocardial infarction, stroke) thrombosis
- History of epilepsy or seizure
- Any known cardiovascular, renal, or liver disorders
- Autoimmune disease
- Sickle cell disease
- Severe hemorrhagic disease
- Placenta previa
- Abnormally invasive placenta (placenta accreta/increta/percreta) abruptio placenta
- Eclampsia
- HELLP syndrome
- Multiple pregnancy
- Intra uterine fetal death
- Allergic to tranexamic acid.

A detailed obstetric history, menstrual history, history of previous medical illnesses and history of the treatment received earlier. A detailed examination of cardiovascular and respiratory system and other systems including thyroid and breast was also noted.

The patients were continuously monitored and the delivery was conducted as per the guidelines.1gm Tranexamic acid IV slowly over 5 minutes + IM oxytocin and IM oxytocin were given after the delivery of the baby to the patients in respective groups.

The details of blood loss were measured following placental delivery to 2 hours after delivery. Vital data, uterine contractility, placental separation, side effects caused by tranexamic acid were noted.

Immediately after delivery of the baby, when all the liquor was drained, a plastic v brass drape was placed
under the buttocks. Blood collected from measuring bag, soaked pads were weighed by electronic scale before and after the delivery.

The quantity of blood loss (ml) was estimated by the weight of the used materials in both the periods pre and post delivery were subtracted. Weight of the materials prior to the delivery, the blood loss measured in bag after placental delivery measured in ml. The pads used after placental delivery to 2 hours postpartum were weighed, the amount of blood loss before baby delivery was thus not included in blood loss in the present study. Hemoglobin and hematocrit were noted before and on 2nd day after delivery. Blood collected in bag and soaked pads were weighed by electronic scale before and after the delivery. This study was approved by ethical review committee of GSL Hospital Rajahmundry.

**Estimation of blood loss**

**Visual method**

Visual method of blood loss estimation is a quick, simple and noninvasive method. Blood loss estimation was done from the onset of third stage of labour to the end of stoppage of active bleeding.7,8

Fixed sized mops were (10x10cm) used in the present study for the estimation of blood loss. The soaking characteristics of the mops were used to estimate total blood loss. Depending on the soakage percentage the blood volume was calculated. Blood spillage on the delivery table, garments and floor were calculated/bag assessed. Total blood loss was calculated.

Hemoglobin/PCV measurement was done at the time of admission and, 48 hours postpartum and its correlation was done with blood loss.

**Gravimetric (measurement by weight) method**

It involves the weighing of collected blood lost during childbirth along with materials such as all contaminated linens, pads, towels, or swabs on a sensitive scale and then deducting the known dry weights of these materials to find out the actual amount of blood loss. The difference in weight was the actual loss in ml. However, other types of fluid, such as amniotic fluid or urine that are present at the time of delivery cannot be avoided or discriminated from the blood during the process of weighing.7,8

**Photometry**

A photometric technique (also known as the alkaline haematin method) involves the conversion of blood pigment to alkaline haematin. This technique is considered as the gold standard for measuring blood; photometric methods are considered the most accurate technique for estimation of blood loss, the procedure poses several limitations.

For research purpose, it can be recommended that combining two methods would be ideal to reduce errors and increase accuracy when measuring postpartum blood loss. Combining the gravimetric method along with direct blood measurement can be proposed as appropriate blood loss estimation technique. This would be a cheap method and increase the accuracy of blood loss estimation.

**Estimation of blood loss after the delivery of placenta**

Estimation of the blood loss in the third stage is grossly inaccurate when this is done by inspection alone. Gatch and little compared photometric estimation of acid hematin, prepared by diluting the patient’s venous blood before and after delivery.9 Coller et al, compared pre and post delivery hemoglobin and plasma protein concentrations.10 Murdoch attempted complete collection in calibrated receptacles.11 Brandt used a washing machine method to measure the blood loss.12 A more accurate method of determining the effects of blood loss and the amount to be replaced involves the measurement of central venous pressure (O’ Driscoll and McCarthy).13

**Statistical analysis**

All the statistical analysis was done by using spss 20.0 software version and MS excel-2007. Descriptive data was presented as mean±standard deviation and percentages. t-test was done to compare the means of different groups. Chi-square test was done to assess the associates among different categorical variables. P<0.05 was considered as statistically significant.

**RESULTS**

The majority of patients in both the groups was aged between 21-26 years and had their BMI between 24-25kg/m².

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Pre-delivery</th>
<th>Post-delivery</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pulse rate</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study group</td>
<td>85.4</td>
<td>85.4</td>
<td>p&gt;0.05</td>
</tr>
<tr>
<td>Control group</td>
<td>85.76</td>
<td>88.6</td>
<td>P&lt;0.01</td>
</tr>
<tr>
<td><strong>SBP</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study group</td>
<td>110.9</td>
<td>110.9</td>
<td>p&gt;0.05</td>
</tr>
<tr>
<td>Control group</td>
<td>110.8</td>
<td>108.2</td>
<td>P&lt;0.01</td>
</tr>
<tr>
<td><strong>DBP</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study group</td>
<td>76.9</td>
<td>76.9</td>
<td>p&gt;0.05</td>
</tr>
<tr>
<td>Control group</td>
<td>76.8</td>
<td>74.2</td>
<td>P&lt;0.01</td>
</tr>
<tr>
<td><strong>Haemoglobin (gm%)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study group</td>
<td>10.4</td>
<td>10.4</td>
<td></td>
</tr>
<tr>
<td>Control group</td>
<td>10.4</td>
<td>10.2</td>
<td></td>
</tr>
</tbody>
</table>
Forty seven patients in study group and forty six patients in control group were primigravida.

Fifty three patients in study group and fifty four patients in control group were second gravida.

The blood loss at the end of two hours was 130ml in study group and 210 ml in control group. The blood loss was significantly low in the study group compared to the control group

The mean increase in pulse rate of 2.84bpm in control group after post delivery (p<0.01), there is no difference in pre and post delivery pulse rate in study group (p>0.05).

The mean fall in systolic Bp in control group is 2.6mmHg and mean fall in diastolic Bp is 2.6mmHg in control group. There is no fall in systolic and diastolic Bp in study group (p>0.05). There is a statistically significant increase in the pulse rate and decrease in blood pressure in the control group as compared with the study group (Table 1).

Table 2: Complications between groups.

<table>
<thead>
<tr>
<th></th>
<th>Study group</th>
<th>Control group</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vomiting and Headache</td>
<td>2</td>
<td>5</td>
<td>0.2</td>
</tr>
<tr>
<td>Need for blood transfusion</td>
<td>0</td>
<td>2</td>
<td>0.1</td>
</tr>
<tr>
<td>Additional uterotonics used</td>
<td>0</td>
<td>3</td>
<td>0.08</td>
</tr>
<tr>
<td>Third stage complications</td>
<td>1</td>
<td>0</td>
<td>0.8</td>
</tr>
</tbody>
</table>

In this study 5% of women had vomitings and headache in oxytocin group. 2% of women in the TXA and oxytocin group p-value was 0.1 which was statistically not significant.

In this study 2% of women needed blood transfusion in oxytocin group. No women in the oxytocin and tranexamic acid group needed blood transfusion and the p-value was 0.1 which was statistically not significant. 3% of women in the control group needed additional oxytocin and carboprost, which was statistically insignificant (p=0.08).

There was no third stage complication in study group, only one patient had PPH in control group. The patients in control group who had postpartum blood loss, lost almost 450-500 ml of blood. There was no incidence of retained placenta or third stage complications in the both groups (Table 2).

In both groups placenta was expelled completely within 5-6 minutes, 98% cases in control and 100% in study group. The duration of third stage of labour was more than 6 min in control group, which was statistically insignificant (p=0.89). There was no incidence of retained placenta in this study.

Table 3: Duration of third stage of labour and hospital stay between groups.

<table>
<thead>
<tr>
<th></th>
<th>Study group</th>
<th>Control group</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration of third stage of labour (minutes)</td>
<td>4</td>
<td>9</td>
<td>8</td>
</tr>
<tr>
<td>Duration of hospital stay (days)</td>
<td>&lt; 3</td>
<td>100</td>
<td>97</td>
</tr>
</tbody>
</table>

Duration of hospital stay was 3% in group I for >3 days stay where as 100% for group-II in <3 days stay which was statistically insignificant (0.08) (Table 3).

DISCUSSION

In the present study, most common age group is between 21-25 years. Majority of the patients in the two groups were between 18-25 years. Very few patients were in the age group between 26-30 years. Age difference in the two groups was not significant (p=0.1).

In the study conducted by Roy P et al, the median maternal age was 23.75 range (20-30) years. There was no statistical significance in the age group. In Ferrer P et al in their study done on 300 women with median age of 23.50 years there was no statistical significance in the both groups. Yang et al in their study on 400 women the median age of 22.75 years there was no statistical difference between the two groups. Gungorkuk et al, in their study on 450 women with the median age of 22.50 years there was no statistical difference between the two groups.

In the present study primi gravida were 47% and 46% in oxytocin group Multigravida 53% and 54% in oxytocin group respectively. There was no statistical significance (p=0.88). Roy P et al in their study primigravida were 10% and 15% in oxytocin group. Multigravida are 40% in study group and 35% in control group there was no statistical difference between the two groups.

The duration of third stage of labour is more than 6 minutes in oxytocin group. There was no influence of the drug in the duration of third stage of labour only 3% of cases in the control group needed uterotonics were two patients needed Inj. carboprost and Inj. Methergine 0.2mg and 2% of patients needed blood transfusion in oxytocin group compared to Tranexamic acid and oxytocin group (p=0.8). The patients in control group who had postpartum blood loss, lost almost 450-500 ml of blood. There was no incidence of retained placenta or third stage complications in the both groups.
In Roy P et al, in his study the mean duration of third stage of labour was 4.6 min in the study group and 4.48 min in the control group. 22% of the patients in the control group needed additional uterotonicics compared to only 2% in the study group. There was a significant difference in the requirement of uterotonicics between the two groups. 10% of the patients in the oxytocin group needed blood transfusion compared to 2% in the study group. There was a significant difference in the need for blood transfusion between the two groups. The patients in the both groups who had postpartum haemorrhage had 400-500 ml blood loss.14

In the present study the average total blood loss with oxytocin is 210.15 and with Tranexamic acid and oxytocin is 131 ml. The mean difference in the blood loss was statistically significant (p<0.05). The blood loss was significantly low in the study group compared to the control group.

In the present study the duration of Hospital stay was >3 days in oxytocin group which was 3% compared to Tranexamic acid group were 100% are discharged with in <3 days (p=0.08).

In Roy’s P study the average total blood loss at the end of two hours was 105 ml in the study group and 250 ml in the control group. The blood loss was significantly low in the study group compared to the control group. In his study there was no significant difference in maternal complications such as vomiting, diarrhoea, headache or fever between the two groups. In his study 12% of the patients in the control group had to stay for more than 3 days compared to 2% in the study group.14

In the present study 2% of women in Tranexamic acid and oxytocin group had vomiting and headache, compared to 5% of oxytocin group and which was statistically not significant (p=0.24).

Majority of patients in both groups were having pre delivery haemoglobin in the range of 10.1-11 gms with a mean of 10.4 in 100% in both groups and which was statistically insignificant (p=0.99). The postdelivery haemoglobin in the range of 10.4 in study group and 10.2 in control group (p=0.08).

In the present study, pre-delivery systolic and diastolic blood pressure are same, after delivery there is a minimal fall in systolic and diastolic blood pressure and increased pulse rate in oxytocin group compared to study group as there is 3% cases needed blood transfusion, which is statistically significant.

In Roy’s P study the mean increase in pulse rate was 1.40 bpm in study group and 5.60 bpm in control group, the mean fall in systolic BP was 1.40 mmHg in the study group and 3.30 mmHg in control group. Mean fall in diastolic BP was 0.50 mmHg in study group and 3.20 mmHg in control group. There was a statistically significant increase in the pulse rate and decrease in blood pressure in the control group as compared to study group.14

The mean fall in haemoglobin was 0.20 gm% in study group and 0.70 gm% in control group. Mean fall in haematoctrit was 0.40% in study group and 1.20% in control group. The postdelivery haemoglobin and haematoctrit were significantly reduced in the control group as compared to the study group. This study showed that tranexamic acid significantly reduces bleeding from time of placental delivery to 2 hours post partum in vaginal delivery. This study shows significant decrease in the incidence of blood loss in the study group as compared to control group (p value <0.05). Similar findings were also reported by Priyankur Roy, Zheng et al showed similar results in vaginal delivery.14,15

This study was a prospective randomized controlled type which showed that TXA significantly reduced bleeding from the time of placental delivery to two hours postpartum in vaginal delivery. This study shows significant decrease in the bleeding volume in TXA group as compared with the placebo group. Roy’s P showed similar comparable results reducing the blood loss in the study group.

Yang et al, reported the measurement of blood loss two hours after delivery 243 ml in study and 314 ml in control group with a p value <0.01 without any side effects.16

Gungorkuk et al reported, mean blood loss during the 3rd and 4th stage of labour, from the end of delivery to 2 hours postpartum the method of measurement of blood loss taken are weight of material used - weight of materials before use. The mean loss in study group 260 ml and 350 ml in control group with a p value <0.001 with mild gastrointestinal side effects and no thromboembolic events.17

Gai et al, showed, mean blood loss was 360 ml in study group and 440 ml in control group, with a p value of 0.002 with no side effects.18

Gohel et al, showed mean blood loss was 375 ml in study group and 470 ml in control group the p value 0.003 with no thromboembolic or other side effects.19

Gulmezogulu AM et al, reported, mean blood loss was 240 ml in study group and 500 ml in control group (p<0.001).20

Therefore the use of TXA appears to reduce the blood loss, severe anemia following postpartum bleeding is an important cause of maternal morbidity and is likely to make more women more vulnerable to fatal postpartum haemorrhage in future pregnancies.

Reducing blood loss would also reduce the risks and costs associated with blood transfusion. The use of TXA
will decrease the risk of transfusion-transmitted viral infections because fewer units of blood will be transfused.

There was no significant alteration in the vital signs of subjects following tranexamic acid administration. There was no abnormalities in hemoglobin, liver and renal function and urine analysis. The incidence of thrombosis during pregnancy and puerperium is 5-6 times higher than that in the general population. When the antifibrinolytic drug, tranexamic acid is administered, the increased rate of postpartum thrombosis after vaginal delivery should be considered.

In the present study, not a single patient developed thrombosis and incidence of side effects like nausea, vomiting and diarrhea were not statistically significant by difference in the two groups.

Administration of TXA in pregnant women may raise concerns about thromboembolism, however previous studies have shown the safety of this drug for use in both pregnant and non pregnant patients. Side effects like nausea, vomiting and diarrhea were not statistically significant by differences in the two groups.

CONCLUSION

In the active management of IIIrd stage of labour 10 IU intramuscular Oxytocin + one gram of tranexamic acid IV is a better combination in reducing the blood loss at delivery when compared to 10 IU intramuscular oxytocin alone. As the advantages are more and the side effects are very minimal with this combination, more studies with this combination are required in the more common vaginal deliveries also to save the mother’s from blood loss.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES
